Evading tumor evasion: Current concepts and perspectives of anti-angiogenic cancer therapy

Drug Resistance Updates

Volumn 13, Issue 1-2, 2010, Pages 16-28

  Abdollahi, Amir ^a,b,c   Folkman, Judah ^b  

^a ST ELIZABETH'S MEDICAL CENTER   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Angiogenesis; Bevacizumab; Evolution; Invasion; Metastasis; Radiotherapy; Resistance; Stroma; Sunitinib

Indexed keywords

ANGIOGENESIS INHIBITOR;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; DRUG RESEARCH; DRUG TARGETING; GENE MUTATION; HUMAN; MALIGNANT NEOPLASTIC DISEASE; METASTASIS; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, NEOPLASM; ENDOTHELIUM, VASCULAR; HUMANS; MODELS, BIOLOGICAL; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 77950948813     PISSN: 13687646     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drup.2009.12.001     Document Type: Article

References (152)

1. Abdollahi A., Gong P., Rastert R., Debus J., Hlatky L., Hahnfeldt P., Maercker C., and Huber P.E. Genome wide expression profiling of irradiated human lung endothelial cells reveals the activation of genes involved in coagulation, inflammation and angiogenic pathways. Proc. Am. Assoc. Cancer Res. 44 (2003) 6155 (Abstract)
2. Abdollahi A., Lipson K.E., Han X., Krempien R., Trinh T., Weber K.J., Hahnfeldt P., Hlatky L., Debus J., Howlett A.R., and Huber P.E. SU5416 and SU6668 attenuate the angiogenic effects of radiation-induced tumor cell growth factor production and amplify the direct anti-endothelial action of radiation in vitro. Cancer Res. 63 (2003) 3755-3763
3. Abdollahi A., Lipson K.E., Sckell A., Zieher H., Klenke F., Poerschke D., Roth A., Han X., Krix M., Bischof M., Hahnfeldt P., Grone H.J., Debus J., Hlatky L., and Huber P.E. Combined therapy with direct and indirect angiogenesis inhibition results in enhanced antiangiogenic and antitumor effects. Cancer Res. 63 (2003) 8890-8898
4. Abdollahi A., Hahnfeldt P., Maercker C., Grone H.J., Debus J., Ansorge W., Folkman J., Hlatky L., and Huber P.E. Endostatin's antiangiogenic signaling network. Mol. Cell 13 (2004) 649-663
5. Abdollahi A., Griggs D.W., Zieher H., Roth A., Lipson K.E., Saffrich R., Grone H.J., Hallahan D.E., Reisfeld R.A., Debus J., Niethammer A.G., and Huber P.E. Inhibition of alpha(v)beta3 integrin survival signaling enhances antiangiogenic and antitumor effects of radiotherapy. Clin. Cancer Res. 11 (2005) 6270-6279
6. Abdollahi A., Hlatky L., and Huber P.E. Endostatin: the logic of antiangiogenic therapy. Drug Resist. Updat. 8 (2005) 59-74
7. Abdollahi A., Li M., Ping G., Plathow C., Domhan S., Kiessling F., Lee L.B., McMahon G., Grone H.J., Lipson K.E., and Huber P.E. Inhibition of platelet-derived growth factor signaling attenuates pulmonary fibrosis. J. Exp. Med. 201 (2005) 925-935
8. Abdollahi A., Schwager C., Kleeff J., Esposito I., Domhan S., Peschke P., Hauser K., Hahnfeldt P., Hlatky L., Debus J., Peters J.M., Friess H., Folkman J., and Huber P.E. Transcriptional network governing the angiogenic switch in human pancreatic cancer. Proc. Natl. Acad. Sci. (USA) 104 (2007) 12890-12895
9. Abedini M.R., Qiu Q., Yan X., and Tsang B.K. Possible role of FLICE-like inhibitory protein (FLIP) in chemoresistant ovarian cancer cells in vitro. Oncogene 23 (2004) 6997-7004
10. Abiatari I., DeOliveira T., Kerkadze V., Schwager C., Esposito I., Giese N.A., Huber P., Bergman F., Abdollahi A., Friess H., and Kleeff J. Consensus transcriptome signature of perineural invasion in pancreatic carcinoma. Mol. Cancer Ther. 8 (2009) 1494-1504
11. Al-Nedawi K., Meehan B., Kerbel R.S., Allison A.C., and Rak J. Endothelial expression of autocrine VEGF upon the uptake of tumor-derived microvesicles containing oncogenic EGFR. Proc. Natl. Acad. Sci. (USA) 106 (2009) 3794-3799
12. Almog N., Ma L., Raychowdhury R., Schwager C., Erber R., Short S., Hlatky L., Vajkoczy P., Huber P.E., Folkman J., and Abdollahi A. Transcriptional switch of dormant tumors to fast-growing angiogenic phenotype. Cancer Res. 69 (2009) 836-844
13. Amin D.N., Bielenberg D.R., Lifshits E., Heymach J.V., and Klagsbrun M. Targeting EGFR activity in blood vessels is sufficient to inhibit tumor growth and is accompanied by an increase in VEGFR-2 dependence in tumor endothelial cells. Microvasc. Res. 76 (2008) 15-22
14. Amin D.N., Hida K., Bielenberg D.R., and Klagsbrun M. Tumor endothelial cells express epidermal growth factor receptor (EGFR) but not ErbB3 and are responsive to EGF and to EGFR kinase inhibitors. Cancer Res. 66 (2006) 2173-2180
15. Bedford J.S., and Dewey W.C. Radiation Research Society. 1952-2002. Historical and current highlights in radiation biology: has anything important been learned by irradiating cells?. Radiat. Res. 158 (2002) 251-291
16. Belka C., Jendrossek V., Pruschy M., Vink S., Verheij M., and Budach W. Apoptosis-modulating agents in combination with radiotherapy-current status and outlook. Int. J. Radiat. Oncol. Biol. Phys. 58 (2004) 542-554
17. Bergsmedh A., Szeles A., Henriksson M., Bratt A., Folkman M.J., Spetz A.L., and Holmgren L. Horizontal transfer of oncogenes by uptake of apoptotic bodies. Proc. Natl. Acad. Sci. (USA) 98 (2001) 6407-6411
18. Bischof M., Abdollahi A., Gong P., Stoffregen C., Lipson K.E., Debus J.U., Weber K.J., and Huber P.E. Triple combination of irradiation, chemotherapy (pemetrexed), and VEGFR inhibition (SU5416) in human endothelial and tumor cells. Int. J. Radiat. Oncol. Biol. Phys. 60 (2004) 1220-1232
19. Blagosklonny M.V. Hypoxia-inducible factor: Achilles' heel of antiangiogenic cancer therapy (review). Int. J. Oncol. 19 (2001) 257-262
20. Blagosklonny M.V. Antiangiogenic therapy and tumor progression. Cancer Cell 5 (2004) 13-17
21. Blanke C.D. Dual-antibody therapy in advanced colorectal cancer: gather ye rosebuds while ye may. J. Clin. Oncol. 27 (2009) 655-658
22. Bonner J.A., Harari P.M., Giralt J., Azarnia N., Shin D.M., Cohen R.B., et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. New Engl. J. Med. 354 (2006) 567-578
23. Branford S., Rudzki Z., Walsh S., Grigg A., Arthur C., Taylor K., Herrmann R., Lynch K.P., and Hughes T.P. High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood 99 (2002) 3472-3475
24. Braun S., Pantel K., Muller P., Janni W., Hepp F., Kentenich C.R., Gastroph S., Wischnik A., Dimpfl T., Kindermann G., Riethmuller G., and Schlimok G. Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. New Engl. J. Med. 342 (2000) 525-533
25. Braun S., Vogl F.D., Naume B., Janni W., Osborne M.P., Coombes R.C., et al. A pooled analysis of bone marrow micrometastasis in breast cancer. New Engl. J. Med. 353 (2005) 793-802
26. Browder T., Butterfield C.E., Kraling B.M., Shi B., Marshall B., O'Reilly M.S., and Folkman J. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res. 60 (2000) 1878-1886
27. Browder T., Folkman J., Hahnfeldt P., Heymach J., Hlatky L., Kieran M., and Rogers M.S. Antiangiogenic therapy and p53. Science 297 (2002) 471
28. Broxterman H.J., and Georgopapadakou N.H. Anticancer therapeutics: a surge of new developments increasingly target tumor and stroma. Drug Resist. Updat. 10 (2007) 182-193
29. Broxterman H.J., Gotink K.J., and Verheul H.M. Understanding the causes of multidrug resistance in cancer: a comparison of doxorubicin and sunitinib. Drug Resist. Updat. 12 (2009) 114-126
30. Burstein H.J., Elias A.D., Rugo H.S., Cobleigh M.A., Wolff A.C., Eisenberg P.D., Lehman M., Adams B.J., Bello C.L., DePrimo S.E., Baum C.M., and Miller K.D. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J. Clin. Oncol. 26 (2008) 1810-1816
31. Camphausen K., Moses M.A., Beecken W.D., Khan M.K., Folkman J., and O'Reilly M.S. Radiation therapy to a primary tumor accelerates metastatic growth in mice. Cancer Res. 61 (2001) 207-2211
32. Carmeliet P., Ferreira V., Breier G., Pollefeyt S., Kieckens L., Gertsenstein M., et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 380 (1996) 435-439
33. Carmeliet P., and Jain R.K. Angiogenesis in cancer and other diseases. Nature 407 (2000) 249-257
34. Casanovas O., Hicklin D.J., Bergers G., and Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 8 (2005) 299-309
35. Celik I., Surucu O., Dietz C., Heymach J.V., Force J., Hoschele I., Becker C.M., Folkman J., and Kisker O. Therapeutic efficacy of endostatin exhibits a biphasic dose-response curve. Cancer Res. 65 (2005) 11044-11050
36. Cervi D., Yip T.T., Bhattacharya N., Podust V.N., Peterson J., Abou-Slaybi A., Naumov G.N., Bender E., Almog N., Italiano Jr. J.E., Folkman J., and Klement G.L. Platelet-associated PF-4 as a biomarker of early tumor growth. Blood 111 (2008) 1201-1207
37. Chait R., Craney A., and Kishony R. Antibiotic interactions that select against resistance. Nature 446 (2007) 668-671
38. Cohen M.H., Li S.Y., Keegan P., and Pazdur R. FDA drug approval summary: bevacizumab (Avastin(R)) as treatment of recurrent glioblastoma multiforme. Oncologist 14 (2009) 1131-1138
39. Combs S.E., Heeger S., Haselmann R., Edler L., Debus J., and Schulz-Ertner D. Treatment of primary glioblastoma multiforme with cetuximab, radiotherapy and temozolomide (GERT)-phase I/II trial: study protocol. BMC Cancer 6 (2006) 133
40. Crawford Y., Kasman I., Yu L., Zhong C., Wu X., Modrusan Z., Kaminker J., and Ferrara N. PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment. Cancer Cell 15 (2009) 21-34
41. De Luca A., Carotenuto A., Rachiglio A., Gallo M., Maiello M.R., Aldinucci D., Pinto A., and Normanno N. The role of the EGFR signaling in tumor microenvironment. J. Cell Physiol. 214 (2008) 559-567
42. Di Sano F., Fazi B., Citro G., Lovat P.E., Cesareni G., and Piacentini M. Glucosylceramide synthase and its functional interaction with RTN-1C regulate chemotherapeutic-induced apoptosis in neuroepithelioma cells. Cancer Res. 63 (2003) 3860-3865
43. Dorrell M.I., Aguilar E., Scheppke L., Barnett F.H., and Friedlander M. Combination angiostatic therapy completely inhibits ocular and tumor angiogenesis. Proc. Natl. Acad. Sci. (USA) 104 (2007) 967-972
44. Duda D.G., Jain R.K., and Willett C.G. Antiangiogenics: the potential role of integrating this novel treatment modality with chemoradiation for solid cancers. J. Clin. Oncol. 25 (2007) 4033-4042
45. Dudley A.C., Khan Z.A., Shih S.C., Kang S.Y., Zwaans B.M., Bischoff J., and Klagsbrun M. Calcification of multipotent prostate tumor endothelium. Cancer Cell 14 (2008) 201-211
46. Ebos J.M., Lee C.R., Christensen J.G., Mutsaers A.J., and Kerbel R.S. Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy. Proc. Natl. Acad. Sci. (USA) 104 (2007) 17069-17074
47. Ebos J.M., Lee C.R., Cruz-Munoz W., Bjarnason G.A., Christensen J.G., and Kerbel R.S. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 15 (2009) 232-239
48. Edwards E., Geng L., Tan J., Onishko H., Donnelly E., and Hallahan D.E. Phosphatidylinositol 3-kinase/Akt signaling in the response of vascular endothelium to ionizing radiation. Cancer Res. 62 (2002) 4671-4677
49. Ehnfors J., Kost-Alimova M., Persson N.L., Bergsmedh A., Castro J., Levchenko-Tegnebratt T., Yang L., Panaretakis T., and Holmgren L. Horizontal transfer of tumor DNA to endothelial cells in vivo. Cell Death Differ. 16 (2009) 749-757
50. Eikesdal H.P., and Kalluri R. Drug resistance associated with antiangiogenesis therapy. Semin. Cancer Biol. 19 (2009) 310-317
51. Elledge S.J., and Hannon G.J. An open letter to cancer researchers. Science 310 (2005) 439-441
52. Ellis L.M., and Hicklin D.J. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat. Rev. Cancer 8 (2008) 579-591
53. Ellis L.M., and Hicklin D.J. Resistance to targeted therapies: refining anticancer therapy in the era of molecular oncology. Clin. Cancer Res. 15 (2009) 7471-7478
54. Ferrara N., Carver-Moore K., Chen H., Dowd M., Lu L., O'Shea K.S., Powell-Braxton L., Hillan K.J., and Moore M.W. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 380 (1996) 439-442
55. Fertil B., and Malaise E.P. Intrinsic radiosensitivity of human cell lines is correlated with radioresponsiveness of human tumors: analysis of 101 published survival curves. Int. J. Radiat. Oncol. Biol. Phys. 11 (1985) 1699-1707
56. Fokt R.M., Templeton A., Gillessen S., Ohlschlegel C., and Schmid H.P. Prostatic metastasis of renal cell carcinoma successfully treated with sunitinib. Urol. Int. 83 (2009) 122-124
57. Folkman J. Tumor angiogenesis: therapeutic implications. New Engl. J. Med. 285 (1971) 1182-1186
58. Folkman J. Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. New Engl. J. Med. 333 (1995) 1757-1763
59. Folkman J. Angiogenesis: an organizing principle for drug discovery?. Nat. Rev. Drug Discov. 6 (2007) 273-286
60. Folkman J., and Camphausen K. Cancer. What does radiotherapy do to endothelial cells?. Science 293 (2001) 227-228
61. Folkman J., Hahnfeldt P., and Hlatky L. Cancer: looking outside the genome. Nat. Rev. Mol. Cell Biol. 1 (2000) 76-79
62. Francia G., Emmenegger U., and Kerbel R.S. Tumor-associated fibroblasts as "Trojan Horse" mediators of resistance to anti-VEGF therapy. Cancer Cell 15 (2009) 3-5
63. Gao D., Nolan D.J., Mellick A.S., Bambino K., McDonnell K., and Mittal V. Endothelial progenitor cells control the angiogenic switch in mouse lung metastasis. Science 319 (2008) 195-198
64. Garcia-Barros M., Paris F., Cordon-Cardo C., Lyden D., Rafii S., Haimovitz-Friedman A., Fuks Z., and Kolesnick R. Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science 300 (2003) 1155-1159
65. Geng L., Donnelly E., McMahon G., Lin P.C., Sierra-Rivera E., Oshinka H., and Hallahan D.E. Inhibition of vascular endothelial growth factor receptor signaling leads to reversal of tumor resistance to radiotherapy. Cancer Res. 61 (2001) 2413-2419
66. Gerdes H.H., and Carvalho R.N. Intercellular transfer mediated by tunneling nanotubes. Curr. Opin. Cell Biol. 20 (2008) 470-475
67. Gorre M.E., Mohammed M., Ellwood K., Hsu N., Paquette R., Rao P.N., and Sawyers C.L. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293 (2001) 876-880
68. Gorski D.H., Beckett M.A., Jaskowiak N.T., Calvin D.P., Mauceri H.J., Salloum R.M., Seetharam S., Koons A., Hari D.M., Kufe D.W., and Weichselbaum R.R. Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res. 59 (1999) 3374-3378
69. Gupta V.K., Jaskowiak N.T., Beckett M.A., Mauceri H.J., Grunstein J., Johnson R.S., et al. Vascular endothelial growth factor enhances endothelial cell survival and tumor radioresistance. Cancer J. 8 (2002) 47-54
70. Hahnfeldt P., Folkman J., and Hlatky L. Minimizing long-term tumor burden: the logic for metronomic chemotherapeutic dosing and its antiangiogenic basis. J. Theor. Biol. 220 (2003) 545-554
71. Hanahan D., and Weinberg R.A. The hallmarks of cancer. Cell 100 (2000) 57-70
72. Hecht J.R., Mitchell E., Chidiac T., Scroggin C., Hagenstad C., Spigel D., et al. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J. Clin. Oncol. 27 (2009) 672-680
73. Hida K., Hida Y., Amin D.N., Flint A.F., Panigrahy D., Morton C.C., and Klagsbrun M. Tumor-associated endothelial cells with cytogenetic abnormalities. Cancer Res. 64 (2004) 8249-8255
74. Hida K., and Klagsbrun M. A new perspective on tumor endothelial cells: unexpected chromosome and centrosome abnormalities. Cancer Res. 65 (2005) 2507-2510
75. Hirota K., and Semenza G.L. Regulation of angiogenesis by hypoxia-inducible factor 1. Crit. Rev. Oncol. Hematol. 59 (2006) 15-26
76. Holmgren L., O'Reilly M.S., and Folkman J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat. Med. 1 (1995) 149-153
77. Huber P.E., Bischof M., Jenne J., Heiland S., Peschke P., Saffrich R., Grone H.J., Debus J., Lipson K.E., and Abdollahi A. Trimodal cancer treatment: beneficial effects of combined antiangiogenesis, radiation, and chemotherapy. Cancer Res. 65 (2005) 3643-3655
78. Hurwitz H., Fehrenbacher L., Novotny W., Cartwright T., Hainsworth J., Heim W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. New Engl. J. Med. 350 (2004) 2335-2342
79. Hynes R.O. Integrins: bidirectional, allosteric signaling machines. Cell 110 (2002) 673-687
80. Inoue M., Hager J.H., Ferrara N., Gerber H.P., and Hanahan D. VEGF-A has a critical, nonredundant role in angiogenic switching and pancreatic beta cell carcinogenesis. Cancer Cell 1 (2002) 193-202
81. Iwamoto F.M., Abrey L.E., Beal K., Gutin P.H., Rosenblum M.K., Reuter V.E., DeAngelis L.M., and Lassman A.B. Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma. Neurology 73 (2009) 1200-1206
82. Jain R.K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307 (2005) 58-62
83. Jain R.K. Lessons from multidisciplinary translational trials on anti-angiogenic therapy of cancer. Nat. Rev. Cancer 8 (2008) 309-316
84. Jensen A.D., Munter M.W., Bischoff H., Haselmann R., Timke C., Krempien R., et al. Treatment of non-small cell lung cancer with intensity-modulated radiation therapy in combination with cetuximab: the NEAR protocol (NCT00115518). BMC Cancer 6 (2006) 122
85. Jones S., Zhang X., Parsons D.W., Lin J.C., Leary R.J., Angenendt P., et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321 (2008) 1801-1806
86. Kaiser J. Genomics. Billion-dollar cancer mapping project steps forward. Science 321 (2008) 26-27
87. Kalluri R., and Zeisberg M. Fibroblasts in cancer. Nat. Rev. Cancer 6 (2006) 392-401
88. Kerbel R., and Folkman J. Clinical translation of angiogenesis inhibitors. Nat. Rev. Cancer 2 (2002) 727-739
89. Kerbel R.S. Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents. Bioessays 13 (1991) 31-36
90. Kerbel R.S., and Kamen B.A. The anti-angiogenic basis of metronomic chemotherapy. Nat. Rev. Cancer 4 (2004) 423-436
91. Kienast Y., von Baumgarten L., Fuhrmann M., Klinkert W.E., Goldbrunner R., Herms J., and Winkler F. Real-time imaging reveals the single steps of brain metastasis formation. Nat. Med. (2009 Dec 20) [doi:10.1038/nm.2072]
92. Kieran M.W., Folkman J., and Heymach J. Angiogenesis inhibitors and hypoxia. Nat. Med. 9 (2003) 1104-1105
93. Kim T.J., Landen C.N., Lin Y.G., Mangala L.S., Lu C., Nick A.M., et al. Combined anti-angiogenic therapy against VEGF and integrin alpha (ν)beta(3) in an orthotopic model of ovarian cancer. Cancer Biol. Ther. (2009) Epub ahead of print
94. Kim Y., Suh N., Sporn M., and Reed J.C. An inducible pathway for degradation of FLIP protein sensitizes tumor cells to TRAIL-induced apoptosis. J. Biol. Chem. 277 (2002) 22320-22329
95. Klein C.A. Parallel progression of primary tumours and metastases. Nat. Rev. Cancer 9 (2009) 302-312
96. Klement G., Baruchel S., Rak J., Man S., Clark K., Hicklin D.J., Bohlen P., and Kerbel R.S. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J. Clin. Invest. 105 (2000) R15-R24
97. Koutras A.K., Krikelis D., Alexandrou N., Starakis I., and Kalofonos H.P. Brain metastasis in renal cell cancer responding to sunitinib. Anticancer Res. 27 (2007) 4255-4257
98. Krempien R., Muenter M.W., Huber P.E., Nill S., Friess H., Timke C., et al. Randomized phase II-study evaluating EGFR targeting therapy with cetuximab in combination with radiotherapy and chemotherapy for patients with locally advanced pancreatic cancer-PARC: study protocol [ISRCTN56652283]. BMC Cancer 5 (2005) 131
99. Kunkel P., Ulbricht U., Bohlen P., Brockmann M.A., Fillbrandt R., Stavrou D., Westphal M., and Lamszus K. Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2. Cancer Res. 61 (2001) 6624-6628
100. Lamszus K., Brockmann M.A., Eckerich C., Bohlen P., May C., Mangold U., Fillbrandt R., and Westphal M. Inhibition of glioblastoma angiogenesis and invasion by combined treatments directed against vascular endothelial growth factor receptor-2, epidermal growth factor receptor, and vascular endothelial-cadherin. Clin. Cancer Res. 11 (2005) 4934-4940
101. Lee S.L., Rouhi P., Dahl J.L., Zhang D., Ji H., Hauptmann G., Ingham P., and Cao Y. Hypoxia-induced pathological angiogenesis mediates tumor cell dissemination, invasion, and metastasis in a zebrafish tumor model. Proc. Natl. Acad. Sci. (USA) 106 (2009) 19485-19490
102. Lee T.Y., Muschal S., Pravda E.A., Folkman J., Abdollahi A., and Javaherian K. Angiostatin regulates the expression of antiangiogenic and pro-apoptotic pathways via targeted inhibition of mitochondrial proteins. Blood 114 (2009) 1987-1998
103. Longley D.B., Wilson T.R., McEwan M., Allen W.L., McDermott U., Galligan L., and Johnston P.G. c-FLIP inhibits chemotherapy-induced colorectal cancer cell death. Oncogene 25 (2006) 838-848
104. Mauceri H.J., Hanna N.N., Beckett M.A., Gorski D.H., Staba M.J., Stellato K.A., et al. Combined effects of angiostatin and ionizing radiation in antitumour therapy. Nature 394 (1998) 287-291
105. Medioni J., Choueiri T.K., Zinzindohoue F., Cho D., Fournier L., and Oudard S. Response of renal cell carcinoma pancreatic metastasis to sunitinib treatment: a retrospective analysis. J. Urol. 181 (2009) 2470-2475
106. Michel J.B., Yeh P.J., Chait R., Moellering Jr. R.C., and Kishony R. Drug interactions modulate the potential for evolution of resistance. Proc. Natl. Acad. Sci. (USA) 105 (2008) 14918-14923
107. Motzer R.J., Hutson T.E., Tomczak P., Michaelson M.D., Bukowski R.M., Oudard S., et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 27 (2009) 3584-3590
108. Motzer R.J., Hutson T.E., Tomczak P., Michaelson M.D., Bukowski R.M., Rixe O., et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. New Engl. J. Med. 356 (2007) 115-124
109. Murray L.J., Abrams T.J., Long K.R., Ngai T.J., Olson L.M., Hong W., Keast P.K., Brassard J.A., O'Farrell A.M., Cherrington J.M., and Pryer N.K. SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model. Clin. Exp. Metastasis 20 (2003) 757-766
110. Muschal S., Lee T.Y., Korn B., Folkman J., Huber P.E., Javaherian K., and Abdollahi A. Identification of novel angiostatin binding partners using a protein array (27K) based high-throughput protein-protein interaction screen. Proc. Am. Assoc. Cancer Res. 378 (2008) (Abstract)
111. Nakagawa T., Tohyama O., Yamaguchi A., et al. E7050: a dual c-Met and VEGFR2 tyrosine kinase inhibitor promotes tumor regression and prolongs survival in Mouse xenograft models. Cancer Sci. (2009 September) Epub ahead of print
112. Ng Q.S., Goh V., Milner J., Padhani A.R., Saunders M.I., and Hoskin P.J. Acute tumor vascular effects following fractionated radiotherapy in human lung cancer: In vivo whole tumor assessment using volumetric perfusion computed tomography. Int. J. Radiat. Oncol. Biol. Phys. 67 (2007) 417-424
113. Nyberg P., Xie L., and Kalluri R. Endogenous inhibitors of angiogenesis. Cancer Res. 65 (2005) 3967-3979
114. O'Reilly M.S., Holmgren L., Shing Y., Chen C., Rosenthal R.A., Moses M., Lane W.S., Cao Y., Sage E.H., and Folkman J. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79 (1994) 315-328
115. Paez-Ribes M., Allen E., Hudock J., Takeda T., Okuyama H., Vinals F., Inoue M., Bergers G., Hanahan D., and Casanovas O. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15 (2009) 220-231
116. Paris F., Fuks Z., Kang A., Capodieci P., Juan G., Ehleiter D., Haimovitz-Friedman A., Cordon-Cardo C., and Kolesnick R. Endothelial apoptosis as the primary lesion initiating intestinal radiation damage in mice. Science 293 (2001) 293-297
117. Parsons D.W., Jones S., Zhang X., Lin J.C., Leary R.J., Angenendt P., et al. An integrated genomic analysis of human glioblastoma multiforme. Science 321 (2008) 1807-1812
118. Pennacchietti S., Michieli P., Galluzzo M., Mazzone M., Giordano S., and Comoglio P.M. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 3 (2003) 347-361
119. Pezzolo A., Parodi F., Corrias M.V., Cinti R., Gambini C., and Pistoia V. Tumor origin of endothelial cells in human neuroblastoma. J. Clin. Oncol. 25 (2007) 376-383
120. Rak J., and Yu J.L. Oncogenes and tumor angiogenesis: the question of vascular "supply" and vascular "demand". Semin. Cancer Biol. 14 (2004) 93-104
121. Rapisarda A., and Melillo G. Role of the hypoxic tumor microenvironment in the resistance to anti-angiogenic therapies. Drug Resist. Updat. 12 (2009) 74-80
122. Relf M., LeJeune S., Scott P.A., Fox S., Smith K., Leek R., Moghaddam A., Whitehouse R., Bicknell R., and Harris A.L. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res. 57 (1997) 963-969
123. Reynolds L.E., Wyder L., Lively J.C., Taverna D., Robinson S.D., Huang X., Sheppard D., Hynes R.O., and Hodivala-Dilke K.M. Enhanced pathological angiogenesis in mice lacking beta3 integrin or beta3 and beta5 integrins. Nat. Med. 8 (2002) 27-34
124. Ruoslahti E. Specialization of tumour vasculature. Nat. Rev. Cancer 2 (2002) 83-90
125. Rustom A., Saffrich R., Markovic I., Walther P., and Gerdes H.H. Nanotubular highways for intercellular organelle transport. Science 303 (2004) 1007-1010
126. Schueneman A.J., Himmelfarb E., Geng L., Tan J., Donnelly E., Mendel D., McMahon G., and Hallahan D.E. SU11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor models. Cancer Res. 63 (2003) 4009-4016
127. Semenza G.L. Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer 3 (2003) 721-732
128. Shah N.P., Nicoll J.M., Nagar B., Gorre M.E., Paquette R.L., Kuriyan J., and Sawyers C.L. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2 (2002) 117-125
129. Shinohara E.T., Cao C., Niermann K., Mu Y., Zeng F., Hallahan D.E., and Lu B. Enhanced radiation damage of tumor vasculature by mTOR inhibitors. Oncogene 24 (2005) 5414-5422
130. Shojaei F., and Ferrara N. Role of the microenvironment in tumor growth and in refractoriness/resistance to anti-angiogenic therapies. Drug Resist. Updat. 11 (2008) 219-230
131. Shojaei F., Wu X., Malik A.K., Zhong C., Baldwin M.E., Schanz S., Fuh G., Gerber H.P., and Ferrara N. Tumor refractoriness to anti-VEGF treatment is mediated by CD11b + Gr1 + myeloid cells. Nat. Biotechnol. 25 (2007) 911-920
132. Shojaei F., Wu X., Qu X., Kowanetz M., Yu L., Tan M., Meng Y.G., and Ferrara N. G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models. Proc. Natl. Acad. Sci. (USA) 106 (2009) 6742-6747
133. Shojaei F., Wu X., Zhong C., Yu L., Liang X.H., Yao J., et al. Bv8 regulates myeloid-cell-dependent tumour angiogenesis. Nature 450 (2007) 825-831
134. Sjoblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D., et al. The consensus coding sequences of human breast and colorectal cancers. Science 314 (2006) 268-274
135. Sonpavde G., Periman P.O., Bernold D., Weckstein D., Fleming M.T., Galsky M.D., et al. Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy. Ann. Oncol. (2009) 10.1093/annonc/mdp323
136. Steeg P.S. Angiogenesis inhibitors: motivators of metastasis?. Nat. Med. 9 (2003) 822-823
137. Stupp R., Mason W.P., van den Bent M.J., Weller M., Fisher B., Taphoorn M.J., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. New Engl. J. Med. 352 (2005) 987-996
138. Szmit S., Zagrodzka M., Kurzyna M., Opolski G., and Szczylik C. Sunitinib malate, a receptor tyrosine kinase inhibitor, is effective in the treatment of restrictive heart failure due to heart metastases from renal cell carcinoma. Cardiology 114 (2009) 67-71
139. Tan J., and Hallahan D.E. Growth factor-independent activation of protein kinase B contributes to the inherent resistance of vascular endothelium to radiation-induced apoptotic response. Cancer Res. 63 (2003) 7663-7667
140. TCGA. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455 (2008) 1061-1068
141. Teicher B.A., Holden S.A., Dupuis N.P., Kakeji Y., Ikebe M., Emi Y., and Goff D. Potentiation of cytotoxic therapies by TNP-470 and minocycline in mice bearing EMT-6 mammary carcinoma. Breast Cancer Res. Treat. 36 (1995) 227-236
142. Timke C., Zieher H., Roth A., Hauser K., Lipson K.E., Weber K.J., Debus J., Abdollahi A., and Huber P.E. Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy. Clin. Cancer Res. 14 (2008) 2210-2219
143. Tjin Tham Sjin R.M., Naspinski J., Birsner A.E., Li C., Chan R., Lo K.M., Gillies S., Zurakowski D., Folkman J., Samulski J., and Javaherian K. Endostatin therapy reveals a U-shaped curve for antitumor activity. Cancer Gene Ther. 13 (2006) 619-627
144. Turzanski J., Grundy M., Shang S., Russell N., and Pallis M. P-glycoprotein is implicated in the inhibition of ceramide-induced apoptosis in TF-1 acute myeloid leukemia cells by modulation of the glucosylceramide synthase pathway. Exp. Hematol. 33 (2005) 62-72
145. Vroling L., van der Veldt A.A., de Haas R.R., Haanen J.B., Schuurhuis G.J., Kuik D.J., van Cruijsen H., et al. Increased numbers of small circulating endothelial cells in renal cell cancer patients treated with sunitinib. Angiogenesis 12 (2009) 69-79
146. Waldren C.A. Classical radiation biology dogma, bystander effects and paradigm shifts. Hum. Exp. Toxicol. 23 (2004) 95-100
147. Wild-Bode C., Weller M., Rimner A., Dichgans J., and Wick W. Sublethal irradiation promotes migration and invasiveness of glioma cells: implications for radiotherapy of human glioblastoma. Cancer Res. 61 (2001) 2744-2750
148. Willett C.G., Duda D.G., di Tomaso E., Boucher Y., Czito B.G., Vujaskovic Z., et al. Complete pathological response to bevacizumab and chemoradiation in advanced rectal cancer. Nat. Clin. Pract. Oncol. 4 (2007) 316-321
149. Willett C.G., Duda D.G., di T.E., Boucher Y., Ancukiewicz M., Sahani D.V., et al. Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study. J. Clin. Oncol. 27 (2009) 3020-3026
150. Yeh P., Tschumi A.I., and Kishony R. Functional classification of drugs by properties of their pairwise interactions. Nat. Genet. 38 (2006) 489-494
151. Yu J.L., Rak J.W., Coomber B.L., Hicklin D.J., and Kerbel R.S. Effect of p53 status on tumor response to antiangiogenic therapy. Science 295 (2002) 1526-1528
152. Zwolak P., Jasinski P., Terai K., Gallus N.J., Ericson M.E., Clohisy D.R., and Dudek A.Z. Addition of receptor tyrosine kinase inhibitor to radiation increases tumour control in an orthotopic murine model of breast cancer metastasis in bone. Eur. J. Cancer 44 (2008) 2506-2517